News

Gilead Sciences (NasdaqGS:GILD) Partners With Global Fund To Supply HIV Prevention Drug
Gilead Sciences (NasdaqGS:GILD) recently announced a partnership with the Global Fund to supply lenacapavir for HIV ...
Gilead's Lenacapavir Plan Faces Global Hurdles As It Commits To No-Profit Access for 2 Million
Gilead will supply lenacapavir to Global Fund countries for HIV prevention, but questions remain amid PEPFAR cuts and funding ...
Gilead in pact to speed up access to new HIV therapy in low-income nations
Gilead Sciences (GILD) stock in focus as the company joins The Global Fund to expand access to lenacapavir, an HIV PrEP ...
BioPharma Dive3h
Gilead signs lenacapavir access deal; Arvinas CEO to step down
The drugmaker will provide, at no profit, doses to treat up to 2 million people in resource-limited countries. Meanwhile, Arvinas' John Houston is retiring from his role leading the biotech.
'Game changer' for HIV prevention in SA as lower-income countries granted access to breakthrough drug
Lower-income countries, including South Africa, gain unprecedented access to lenacapavir, a revolutionary HIV prevention drug ...
The News International4h
Gilead, Global Fund finalise plan to supply HIV prevention drug to poor countries
Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalised plans to ...
Poorer countries granted access to HIV prevention drug
Lower-income countries will gain access to a "game-changing" HIV prevention drug with a new deal signed between US ...
STAT6h
Gilead to provide HIV prevention drug to 2 million people in lower-income countries at cost
Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...
Devdiscourse7h
Gilead Sciences to Deliver HIV Prevention Drug to Low-Income Countries
Gilead Sciences, in partnership with the Global Fund, plans to supply a long-acting HIV prevention drug to low-income ...